Discovery of Clinical Candidate GDC-8264, a Novel, Potent and Selective RIP1 Inhibitor for Amelioration of Tissue Damage and the Treatment of Inflammatory Diseases

Post time 2026-5-7 15:34:41

journal：Journal of Medicinal Chemistry

Authors：Snahel Patel; Huifen Chen; Eugene Varfolomeev; Youngsu Kwon; Sreemathy Ramaswamy; Pawan Bir Kohli; John G. Quinn; Joshua D. Webster; Jialin Mao; Yuan Chen; Rina Fong; F. Esra Demircioglu; Patrick Lupardus; Craig Stivala; Gregory L. Hamilton; Michael Siu; Swathi Sujatha-Bhaskar; Vishnu Mohanan; Adeyemi O. Adedeji; Sara F. Santagostino; Jonathan Maher; Brent McKenzie; Michael E. Rothenberg; Adam Johnson; Domagoj Vucic

Published date：2025-11-13

DOI：10.1021/acs.jmedchem.5c01891

PDF link：https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5c01891

Article link：https://doi.org/10.1021/acs.jmedchem.5c01891

Article Source：American Chemical Society (ACS)。

Remark：

Post time 2026-5-7 15:34:42

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Other] Discovery of Clinical Candidate GDC-8264, a Novel, Potent and Selective RIP1 Inhibitor for Amelioration of Tissue Damage and the Treatment of Inflammatory Diseases

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Discovery of Clinical Candidate GDC-8264, a Novel, Potent and Selective RIP1 Inhibitor for Amelioration of Tissue Damage and the Treatment of Inflammatory Diseases Copy

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Discovery of Clinical Candidate GDC-8264, a Novel, Potent and Selective RIP1 Inhibitor for Amelioration of Tissue Damage and the Treatment of Inflammatory Diseases